RFG Advisory LLC Has $1.27 Million Stock Position in Pfizer Inc. $PFE

RFG Advisory LLC cut its holdings in shares of Pfizer Inc. (NYSE:PFE) by 34.1% in the third quarter, HoldingsChannel reports. The fund owned 49,943 shares of the biopharmaceutical company’s stock after selling 25,886 shares during the quarter. RFG Advisory LLC’s holdings in Pfizer were worth $1,273,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of PFE. Curio Wealth LLC increased its stake in Pfizer by 36,600.0% in the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 1,098 shares during the period. Grey Fox Wealth Advisors LLC purchased a new position in shares of Pfizer during the 3rd quarter valued at $29,000. Harbor Asset Planning Inc. acquired a new position in shares of Pfizer in the second quarter worth $29,000. Howard Hughes Medical Institute purchased a new stake in shares of Pfizer during the second quarter worth $30,000. Finally, True Wealth Design LLC boosted its position in Pfizer by 302.5% during the third quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 974 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q4 beat and upbeat outlook: Pfizer reported Q4 EPS and revenue above expectations and reiterated a positive forward outlook, which is supporting the rally as investors price in steadier earnings. Pfizer Reports Strong Earnings Outlook – Unusual Call Options Activity Shows Investors are Bullish
• Positive Sentiment: Unusual options flow: Elevated call-option activity suggests some traders are positioning for further upside after the results, amplifying short‑term bullish momentum. Pfizer Reports Strong Earnings Outlook – Unusual Call Options Activity Shows Investors are Bullish
• Positive Sentiment: Shareholder returns: Management returned $9.8B to shareholders in 2025 (buybacks/dividends), which supports valuation and income-focused investor demand. Pfizer (PFE) Closes 2025 on Solid Note, Returns $9.8B to Shareholders
• Positive Sentiment: Regulatory progress: The FDA granted priority review for HYMPAVZI (marstacimab) sBLA, a pipeline milestone that could add upside if approved. Pfizer Inc. (PFE) announces FDA’s grant of priority review for HYMPAVZI® (marstacimab) sBLA
• Neutral Sentiment: Analyst / press commentary: Several outlets (Seeking Alpha, The Motley Fool, Zacks) publish bullish post‑earnings takes and “look again” pieces that may attract retail interest—but these are opinion pieces rather than new company actions. Pfizer: A Great Opportunity Post Earnings
• Neutral Sentiment: One‑time SEC collection: Pfizer will receive $29M related to an SEC matter tied to a 2013 case—positive to cash flow but immaterial to fundamentals. Pfizer to collect $29 million from SEC case against Steven A. Cohen hedge fund
• Negative Sentiment: Patent cliff and pipeline questions: Analysts and commentary warn of a 2026–2030 patent cliff as COVID-era sales wane; questions remain whether new and acquired drugs will offset lost revenue, pressuring longer‑term growth expectations. Can Pfizer’s New & Acquired Drugs Offset Its Looming Patent Cliff?
• Negative Sentiment: Valuation / “value trap” concerns: Critical pieces highlight execution risk and that the stock’s depressed valuation may reflect real growth challenges—these narratives can cap multiple expansion. Is Pfizer Stock Now A Value Trap?

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on PFE. Bank of America cut their price target on Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a research note on Monday, December 15th. Zacks Research downgraded Pfizer from a “hold” rating to a “strong sell” rating in a report on Monday, January 26th. BMO Capital Markets reiterated an “outperform” rating on shares of Pfizer in a research note on Wednesday, December 10th. Wolfe Research set a $24.00 price target on shares of Pfizer and gave the stock an “underperform” rating in a research note on Wednesday, December 17th. Finally, Sanford C. Bernstein restated a “market perform” rating and set a $30.00 price target on shares of Pfizer in a report on Friday, October 31st. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $28.06.

Pfizer Trading Up 0.5%

Shares of PFE stock opened at $27.74 on Thursday. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $27.94. The company has a market cap of $157.70 billion, a PE ratio of 20.39 and a beta of 0.47. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62. The business’s 50 day moving average is $25.74 and its two-hundred day moving average is $25.15.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.25%. The business had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. During the same period in the previous year, the company earned $0.63 earnings per share. Pfizer’s revenue for the quarter was down 1.2% on a year-over-year basis. Equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.2%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s dividend payout ratio (DPR) is currently 126.47%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.